ecancermedicalscience

Erratum

Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayeasian network meta-analysis

12 Oct 2021
Victor Hugo Fonseca de Jesus, Rachel P Riechelmann

Throughout the text, please consider that the primary outcome of the PRODIGE24 trial was disease-free survival, and not overall survival.

Related Articles

Marina Junqueira de Almeida, Marcos Pedro Guedes Camandaroba, Antonio Paulo Nassar Jr, Victor Hugo Fonseca de Jesus
Andry Lalaina Rinà Rakotozafindrabe, Chantelli Iamblaudiot Razafindrazoto, Domoina Harivonjy Hasina Laingonirina, Tojonokoloina Benjamin Ralideramanambina, Behoavy Mahafaly Ralaizanaka, Sonny Maherison, Jolivet Auguste Rakotomalala, Nitah Harivony Randriamifidy, Anjaramalala Sitraka Rasolonjatovo, Tovo Harimanana Rabenjanahary, Soloniaina Hélio Razafimahefa, Rado Manitrala Ramanampamonjy
Debdeep Dey, Bhagat Singh Lali, Paromita Roy, Divya Midha, Indu Arun, Lateef Zameer, Anand Bardia, Geetashree Mukherjee
Tsion Afework, Birtukan Seid, Aderaw Anteneh, Wondimu Ayele, Seifu Hagos Gebreyesus, Bilal Shikur Endris
Juan Francisco Olivos Gonzáles, Rodrigo Arroyo-Gárate, Miguel Angel Leon Estrella, Gustavo Cerrillo, Stefanie Campos Medina
Hasan Nassereldine, Hussein Awada, Adel Hajj Ali, Mohammad Zeineddine, Zahy Abdul Sater, Yasser Shaib